The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of…

CancerImmunotherapyPD-1+2 more

~Estimated

~$10 – $1,050

Oxford Biodynamics Inc.NCT06635954

Phase 2

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has…

Breast CancerTriple Negative Breast CancerPD-L1 Negative

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04468061